A number of other research firms have also weighed in on LLY. BMO Capital Markets reiterated a buy rating and issued a $94.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 27th. Zacks Investment Research upgraded Eli Lilly and from a hold rating to a buy rating and set a $93.00 price target for the company in a research report on Friday, July 29th. Deutsche Bank AG reiterated a buy rating on shares of Eli Lilly and in a research report on Tuesday, September 20th. Citigroup Inc. reiterated a buy rating on shares of Eli Lilly and in a research report on Wednesday, August 3rd. Finally, Credit Suisse Group AG reiterated a buy rating on shares of Eli Lilly and in a research report on Tuesday, June 28th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $97.06.
Shares of Eli Lilly and (NYSE:LLY) opened at 82.09 on Friday. The stock’s 50 day moving average price is $79.44 and its 200-day moving average price is $77.49. The stock has a market cap of $86.83 billion, a PE ratio of 35.38 and a beta of 0.17. Eli Lilly and has a one year low of $67.88 and a one year high of $88.16.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the business posted $0.90 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and will post $3.59 earnings per share for the current fiscal year.
In other news, insider Maria A. Crowe sold 2,248 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the sale, the insider now owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jackson P. Tai acquired 5,773 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were purchased at an average cost of $80.43 per share, for a total transaction of $464,322.39. Following the acquisition, the director now directly owns 42,306 shares in the company, valued at approximately $3,402,671.58. The disclosure for this purchase can be found here. 0.20% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in the company. Eaton Vance Management raised its stake in shares of Eli Lilly and by 72.3% in the second quarter. Eaton Vance Management now owns 5,498,527 shares of the company’s stock valued at $433,009,000 after buying an additional 2,307,920 shares during the last quarter. Renaissance Technologies LLC increased its position in Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock valued at $159,402,000 after buying an additional 1,880,800 shares during the period. Beutel Goodman & Co Ltd. bought a new position in Eli Lilly and during the second quarter valued at approximately $104,345,000. Janus Capital Management LLC increased its position in Eli Lilly and by 15.9% in the second quarter. Janus Capital Management LLC now owns 10,021,381 shares of the company’s stock valued at $789,162,000 after buying an additional 1,377,814 shares during the period. Finally, Vanguard Group Inc. increased its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock valued at $4,979,889,000 after buying an additional 1,350,329 shares during the period. 74.96% of the stock is currently owned by institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.